# CYP2U1

## Overview
CYP2U1 is a gene that encodes the enzyme cytochrome P450 family 2 subfamily U member 1, a member of the cytochrome P450 superfamily of enzymes. This enzyme is categorized as a monooxygenase and is primarily involved in the metabolism of long-chain fatty acids through ω- and (ω-1)-hydroxylation, producing bioactive eicosanoids that play significant roles in various physiological processes, including blood flow regulation and immune function (Chuang2004CYP2U1; Dhers2017Cytochrome). CYP2U1 is predominantly expressed in the brain and thymus, suggesting its importance in neuronal and immune system functions (Ducassou2017Membranebound). Mutations in the CYP2U1 gene are linked to hereditary spastic paraplegia type 56 (SPG56), a rare neurodegenerative disorder characterized by progressive spasticity and other neurological symptoms (Guo2023Clinical; Bibi2020Rare).

## Structure
The human cytochrome P450 2U1 (CYP2U1) is a unique member of the cytochrome P450 family, characterized by its distinct molecular structure. The primary structure of CYP2U1 is notable for its length, with 544 amino acids, making it the longest isoform in the CYP2 family. It features a longer N-terminal region with eight proline residues and a unique 20 amino acid insert containing five arginine residues, termed insert AA', located between helices A' and A (Ducassou2017Membranebound; Dhers2017Cytochrome).

The secondary structure of CYP2U1 includes a flexible transmembrane helix (TMH) and additional helices, with the N-terminal region predicted to have a helical structure close to the membrane-spanning domain (Ducassou2017Membranebound). The tertiary structure of CYP2U1 has been modeled to show interactions with a POPC membrane, with specific loops and helices interacting with the membrane, such as the N-terminal linker to TMH and insert AA' (Ducassou2017Membranebound). The quaternary structure details are not explicitly mentioned in the available context.

CYP2U1 is primarily expressed in the brain and thymus, with its structure suggesting roles in substrate recruitment and membrane anchoring (Ducassou2017Membranebound; Dhers2017Cytochrome).

## Function
CYP2U1 is a cytochrome P450 enzyme involved in the ω- and (ω-1)-hydroxylation of long-chain fatty acids, such as arachidonic acid and docosahexaenoic acid. This enzymatic activity results in the production of bioactive eicosanoids, including 19-HETE and 20-HETE, which are important for various physiological processes like the regulation of local blood flow, smooth muscle cell activity, cytokine secretion, cell proliferation, and migration (Chuang2004CYP2U1). CYP2U1 is primarily expressed in the thymus and brain, particularly in the cerebellum, and plays a significant role in fatty acid signaling pathways, potentially influencing neuronal, cardiovascular, and immune functions (Chuang2004CYP2U1; Dhers2017Cytochrome).

The enzyme is located in the endoplasmic reticulum of cells and is involved in the metabolism of both saturated and unsaturated fatty acids, converting them into more polar, water-soluble products (Chuang2004CYP2U1). CYP2U1's activity is crucial for maintaining lipid homeostasis and may impact cerebral endothelial homeostasis and blood homeostasis by metabolizing endogenous substrates like arachidonic acid (Jarrar2013Identification). Its expression is influenced by factors such as alcohol and tobacco use, which can alter its levels in the brain (Dhers2017Cytochrome).

## Clinical Significance
Mutations in the CYP2U1 gene are associated with hereditary spastic paraplegia type 56 (SPG56), a rare autosomal recessive disorder. SPG56 is characterized by progressive spasticity and weakness of the lower limbs, often accompanied by additional neurological symptoms such as intellectual disability, dystonia, and cerebellar ataxia (Guo2023Clinical; Bibi2020Rare). The condition can also present with visual impairments, including pigmentary degenerative maculopathy, as observed in some patients (Leonardi2016Pigmentary).

The pathogenicity of CYP2U1 mutations is linked to the enzyme's role in fatty acid metabolism. Missense mutations can lead to altered enzymatic activity, resulting in improper heme binding and protein instability, which contribute to the disease phenotype (Durand2017CYP2U1). For instance, mutations such as p.Cys490Tyr and p.Arg488Trp disrupt heme binding, leading to a loss of enzyme activity (Durand2017CYP2U1).

Clinical manifestations of SPG56 can vary significantly, with some patients experiencing early-onset spasticity and others presenting with additional complications like retinal anomalies or thin corpus callosum (Sallo2023Characterisation; Masciullo2016Hereditary). Genetic testing and molecular analysis are crucial for diagnosing SPG56 and understanding the variability in its clinical presentation (Masciullo2016Hereditary).


## References


[1. (Jarrar2013Identification) Yazun B. Jarrar, Sun-Ah Cho, Kyung-Suk Oh, Dong-Hyun Kim, Jae-Gook Shin, and Su-Jun Lee. Identification of cytochrome p450s involved in the metabolism of arachidonic acid in human platelets. Prostaglandins, Leukotrienes and Essential Fatty Acids, 89(4):227–234, September 2013. URL: http://dx.doi.org/10.1016/j.plefa.2013.06.008, doi:10.1016/j.plefa.2013.06.008. This article has 32 citations.](https://doi.org/10.1016/j.plefa.2013.06.008)

[2. (Durand2017CYP2U1) Christelle M. Durand, Laura Dhers, Christelle Tesson, Alessandra Tessa, Laetitia Fouillen, Stéphanie Jacqueré, Laure Raymond, Isabelle Coupry, Giovanni Benard, Frédéric Darios, Khalid H. El- Hachimi, Guja Astrea, François Rivier, Guillaume Banneau, Claire Pujol, Didier Lacombe, Alexandra Durr, Patrick J. Babin, Filippo M. Santorelli, Nicolas Pietrancosta, Jean-Luc Boucher, Daniel Mansuy, Giovanni Stevanin, and Cyril Goizet. Cyp2u1 activity is altered by missense mutations in hereditary spastic paraplegia 56. Human Mutation, 39(1):140–151, November 2017. URL: http://dx.doi.org/10.1002/humu.23359, doi:10.1002/humu.23359. This article has 21 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.23359)

[3. (Ducassou2017Membranebound) Lionel Ducassou, Laura Dhers, Gabriella Jonasson, Nicolas Pietrancosta, Jean-Luc Boucher, Daniel Mansuy, and François André. Membrane-bound human orphan cytochrome p450 2u1: sequence singularities, construction of a full 3d model, and substrate docking. Biochimie, 140:166–175, September 2017. URL: http://dx.doi.org/10.1016/j.biochi.2017.07.007, doi:10.1016/j.biochi.2017.07.007. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.biochi.2017.07.007)

4. (Guo2023Clinical) Clinical and genetic characteristics of CYP2U1-associated hereditary spastic paraplegia in three children from China. This article has 0 citations.

[5. (Dhers2017Cytochrome) L. Dhers, L. Ducassou, J.-L. Boucher, and D. Mansuy. Cytochrome p450 2u1, a very peculiar member of the human p450s family. Cellular and Molecular Life Sciences, 74(10):1859–1869, January 2017. URL: http://dx.doi.org/10.1007/s00018-016-2443-3, doi:10.1007/s00018-016-2443-3. This article has 21 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00018-016-2443-3)

[6. (Masciullo2016Hereditary) M. Masciullo, A. Tessa, S. Perazza, F.M. Santorelli, A. Perna, and G. Silvestri. Hereditary spastic paraplegia: novel mutations and expansion of the phenotype variability in spg56. European Journal of Paediatric Neurology, 20(3):444–448, May 2016. URL: http://dx.doi.org/10.1016/j.ejpn.2016.02.001, doi:10.1016/j.ejpn.2016.02.001. This article has 22 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ejpn.2016.02.001)

7. (Sallo2023Characterisation) Characterisation of the retinal phenotype using multimodal imaging in novel compound heterozygote variants ofCYP2U1. This article has 1 citations.

[8. (Chuang2004CYP2U1) Samuel S. Chuang, Christian Helvig, Mohammed Taimi, Heather A. Ramshaw, Andrew H. Collop, Ma’an Amad, Jay A. White, Martin Petkovich, Glenville Jones, and Bozena Korczak. Cyp2u1, a novel human thymus- and brain-specific cytochrome p450, catalyzes ω- and (ω-1)-hydroxylation of fatty acids. Journal of Biological Chemistry, 279(8):6305–6314, February 2004. URL: http://dx.doi.org/10.1074/JBC.M311830200, doi:10.1074/jbc.m311830200. This article has 194 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/JBC.M311830200)

[9. (Leonardi2016Pigmentary) Luca Leonardi, Lucia Ziccardi, Christian Marcotulli, Anna Rubegni, Antonino Longobardi, Mariano Serrao, Eugenia Storti, Francesco Pierelli, Alessandra Tessa, Vincenzo Parisi, Filippo M. Santorelli, and Casali Carlo. Pigmentary degenerative maculopathy as prominent phenotype in an italian spg56/cyp2u1 family. Journal of Neurology, 263(4):781–783, February 2016. URL: http://dx.doi.org/10.1007/s00415-016-8066-7, doi:10.1007/s00415-016-8066-7. This article has 25 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00415-016-8066-7)

[10. (Bibi2020Rare) Farah Bibi, Stephanie Efthymiou, Thomas Bourinaris, Ambreen Tariq, Faisal Zafar, Nouzhat Rana, Vincenzo Salpietro, Henry Houlden, Ghazala Kaukab Raja, Sadia Saeed, and Nasir Mahmood Minhas. Rare novel cyp2u1 and zfyve26 variants identified in two pakistani families with spastic paraplegia. Journal of the Neurological Sciences, 411:116669, April 2020. URL: http://dx.doi.org/10.1016/j.jns.2020.116669, doi:10.1016/j.jns.2020.116669. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.jns.2020.116669)